495 related articles for article (PubMed ID: 30353228)
1. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.
Nicolatou-Galitis O; Kouri M; Papadopoulou E; Vardas E; Galiti D; Epstein JB; Elad S; Campisi G; Tsoukalas N; Bektas-Kayhan K; Tan W; Body JJ; Migliorati C; Lalla RV;
Support Care Cancer; 2019 Feb; 27(2):383-394. PubMed ID: 30353228
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptives and osteonecrosis of the jaw.
Yamashita J; McCauley LK
J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
Fusco V; Santini D; Armento G; Tonini G; Campisi G
Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
[TBL] [Abstract][Full Text] [Related]
5. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice.
Kuroshima S; Yamashita J
Bone; 2013 Sep; 56(1):101-9. PubMed ID: 23727433
[TBL] [Abstract][Full Text] [Related]
9. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
10. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
Schiodt M; Vadhan-Raj S; Chambers MS; Nicolatou-Galitis O; Politis C; Coropciuc R; Fedele S; Jandial D; Zhang J; Ma H; Saunders DP
Support Care Cancer; 2018 Jun; 26(6):1905-1915. PubMed ID: 29275525
[TBL] [Abstract][Full Text] [Related]
11. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
12. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.
Nicolatou-Galitis O; Razis E; Galiti D; Galitis E; Labropoulos S; Tsimpidakis A; Sgouros J; Karampeazis A; Migliorati C
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):699-706. PubMed ID: 26455289
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Fusco V; Porta C; Saia G; Paglino C; Bettini G; Scoletta M; Bonacina R; Vescovi P; Merigo E; Lo Re G; Guglielmini P; Di Fede O; Campisi G; Bedogni A
Clin Genitourin Cancer; 2015 Aug; 13(4):287-294. PubMed ID: 25586958
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.
Ruggiero SL
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):479-87. PubMed ID: 26293329
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.
Campisi G; Fedele S; Fusco V; Pizzo G; Di Fede O; Bedogni A
Future Oncol; 2014 Feb; 10(2):257-75. PubMed ID: 24490612
[TBL] [Abstract][Full Text] [Related]
16. Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw.
de Boissieu P; Trenque T
Expert Opin Drug Saf; 2015 Jul; 14(7):1015-21. PubMed ID: 25943856
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of healing time of osteochemonecrosis of the jaw after surgery: Single-center retrospective study and review of the literature].
Berquet A; Louvrier A; Denis F; Bornert F; Weber E; Meyer C
J Stomatol Oral Maxillofac Surg; 2017 Feb; 118(1):11-19. PubMed ID: 28330568
[TBL] [Abstract][Full Text] [Related]
18. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis and osteonecrosis of the jaw (ONJ).
Kim HK
J Musculoskelet Neuronal Interact; 2007; 7(4):348-9. PubMed ID: 18094508
[No Abstract] [Full Text] [Related]
20. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
Querrer R; Ferrare N; Melo N; Stefani CM; Dos Reis PED; Mesquita CRM; Borges GA; Leite AF; Figueiredo PT
Support Care Cancer; 2021 Jun; 29(6):2811-2820. PubMed ID: 33140246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
